D. Ross Camidge, MD, PhD, is a professor of medicine-medical oncology, and director of the Thoracic Oncology Clinical Program and Clinical Research Program at the University of Colorado Cancer Center – Anschutz Medical Campus.
Camidge and Wilfong on Making A Difference Through a Career in Continuing Medical Education
September 12th 2024D. Ross Camidge, MD, PhD, and Kadrin Wilfong, MD discuss Wilfong's passion for continuing medical education (CME) and how CME events and resources can make a difference in the care of patients with cancer.
Read More
Key Takeaways in HER2-Mutated NSCLC
The panel concludes the discussion with key takeaways on the evolving treatment landscape in HER2 non–small cell lung cancer.
Read More
Treatment Considerations in HER2-Mutated NSCLC
Experts on HER2 NSCLC provide clinical insights on selecting between antibody-drug conjugates and TKIs, treatment sequencing, and the role of chemoimmunotherapy.
Read More
Challenges and Unmet Needs in HER2-Mutated NSCLC
The expert panel shares its thoughts on current challenges and unmet needs in the overall HER2-mutated non–small cell lung cancer treatment landscape.
Read More
Adverse Events Associated With TKIs in HER2-Mutated NSCLC
D. Ross Camidge, MD, PhD, discusses the main adverse events seen with TKIs in patients with HER2-mutated non–small cell lung cancer.
Read More
First-in-Human Study of BAY2927088 in Advanced HER2-Mutated NSCLC
Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.
Read More
Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC
The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.
Read More
The Potential Role of TKIs in HER2-Mutated NSCLC
Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.
Read More
Managing Adverse Events Associated With ADCs in HER2-Mutated NSCLC
Lyudmila A. Bazhenova, MD, an expert on non–small cell lung cancer, provides clinical insights on the management of adverse events associated with antibody-drug conjugates.
Read More